Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models

被引:160
作者
Bandyopadhyay, Abhik [1 ]
Wang, Long [1 ]
Agyin, Joseph [2 ]
Tang, Yuping [1 ]
Lin, Shu [1 ]
Yeh, I-Tien [3 ]
De, Keya [1 ]
Sun, Lu-Zhe [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA
[3] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA
来源
PLOS ONE | 2010年 / 5卷 / 04期
关键词
GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR KINASE INHIBITOR; IN-VIVO; STEM-CELLS; MAMMARY-CARCINOMA; TRANSFORMING GROWTH-FACTOR-BETA-1; DISEASE PROGRESSION; MDA-MB-231; CELLS; DRUG-RESISTANCE;
D O I
10.1371/journal.pone.0010365
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Recent studies suggested that induction of epithelial-mesenchymal transition (EMT) might confer both metastatic and self-renewal properties to breast tumor cells resulting in drug resistance and tumor recurrence. TGF beta is a potent inducer of EMT and has been shown to promote tumor progression in various breast cancer cell and animal models. Principal Findings: We report that chemotherapeutic drug doxorubicin activates TGF beta signaling in human and murine breast cancer cells. Doxorubicin induced EMT, promoted invasion and enhanced generation of cells with stem cell phenotype in murine 4T1 breast cancer cells in vitro, which were significantly inhibited by a TGF beta type I receptor kinase inhibitor (T beta RI-KI). We investigated the potential synergistic anti-tumor activity of T beta R1-KI in combination with doxorubicin in animal models of metastatic breast cancer. Combination of Doxorubicin and T beta RI-KI enhanced the efficacy of doxorubicin in reducing tumor growth and lung metastasis in the 4T1 orthotopic xenograft model in comparison to single treatments. Doxorubicin treatment alone enhanced metastasis to lung in the human breast cancer MDA-MB-231 orthotopic xenograft model and metastasis to bone in the 4T1 orthotopic xenograft model, which was significantly blocked when T beta R1-KI was administered in combination with doxorubicin. Conclusions: These observations suggest that the adverse activation of TGF beta pathway by chemotherapeutics in the cancer cells together with elevated TGF beta levels in tumor microenvironment may lead to EMT and generation of cancer stem cells resulting in the resistance to the chemotherapy. Our results indicate that the combination treatment of doxorubicin with a TGF beta inhibitor has the potential to reduce the dose and consequently the toxic side-effects of doxorubicin, and improve its efficacy in the inhibition of breast cancer growth and metastasis.
引用
收藏
页数:13
相关论文
共 58 条
  • [1] Inhibition of TGFβ signaling in cancer therapy
    Arteaga, CL
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2006, 16 (01) : 30 - 37
  • [2] Bandyopadhyay A, 2002, CANCER RES, V62, P4690
  • [3] Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor
    Bandyopadhyay, Abhik
    Agyin, Joseph K.
    Wang, Long
    Tang, Yuping
    Lei, Xiufen
    Story, Beryl M.
    Cornell, John E.
    Pollock, Bradley H.
    Mundy, Gregory R.
    Sun, Lu-Zhe
    [J]. CANCER RESEARCH, 2006, 66 (13) : 6714 - 6721
  • [4] Bandyopadhyay Abhik, 2008, V2, P723, DOI 10.1007/978-1-59745-293-9_44
  • [5] Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression
    Biswas, Swati
    Guix, Marta
    Rinehart, Cammie
    Dugger, Teresa C.
    Chytil, Anna
    Moses, Harold L.
    Freeman, Michael L.
    Arteaga, Carlos L.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) : 1305 - 1313
  • [6] A pooled analysis of bone marrow micrometastasis in breast cancer
    Braun, S
    Vogl, FD
    Naume, B
    Janni, W
    Osborne, MP
    Coombes, RC
    Schlimok, G
    Diel, IJ
    Gerber, B
    Gebauer, G
    Pierga, JY
    Marth, C
    Oruzio, D
    Wiedswang, G
    Solomayer, EF
    Kundt, G
    Strobl, B
    Fehm, T
    Wong, GYC
    Bliss, J
    Vincent-Salomon, A
    Pantel, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) : 793 - 802
  • [7] Cancer stem cells in breast: Current opinion and future challenges
    Charafe-Jauffret, Emmanuelle
    Monville, Florence
    Ginestier, Christophe
    Dontu, Gabriela
    Birnbaum, Daniel
    Wicha, Max S.
    [J]. PATHOBIOLOGY, 2008, 75 (02) : 75 - 84
  • [8] Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
    Charafe-Jauffret, Emmanuelle
    Ginestier, Christophe
    Iovino, Flora
    Wicinski, Julien
    Cervera, Nathalie
    Finetti, Pascal
    Hur, Min-Hee
    Diebel, Mark E.
    Monville, Florence
    Dutcher, Julie
    Brown, Marty
    Viens, Patrice
    Xerri, Luc
    Bertucci, Francois
    Stassi, Giorgio
    Dontu, Gabriela
    Birnbaum, Daniel
    Wicha, Max S.
    [J]. CANCER RESEARCH, 2009, 69 (04) : 1302 - 1313
  • [9] Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model
    Chen, JH
    Ling, R
    Yao, Q
    Li, Y
    Chen, T
    Wang, Z
    Li, KZ
    [J]. ENDOCRINE-RELATED CANCER, 2005, 12 (01) : 93 - 100
  • [10] DALAL BI, 1993, AM J PATHOL, V143, P381